ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
AbbVie
The role is a Principal Research Scientist II in AbbVie's Purification Development group within the Biologics Drug Substance Development organization. Based at the AbbVie Bioresearch Center in Worcester, MA, the group supports end-to-end development of downstream processes for biologics from early development through late-stage optimization. The role contributes to innovation in downstream technologies and the development of cost-effective manufacturing processes for biologics.
Headquarters
North Chicago, Illinois, United States
Company Size
10001+ employees
Founded
2013
AbbVie is a biopharmaceutical company that develops and markets prescription medicines in areas including immunology, oncology, neuroscience, eye care, and aesthetics. It is the French website of AbbVie, the global pharmaceutical company formed as a spin-off from Abbott Laboratories.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for AbbVie.
AbbVie didn’t post a salary, so this is our estimate from similar listings.
9% above the average for this role
Senior Scientist II, Early Pipeline Development
Novartis
Senior Process Engineer - Manufacturing Sciences & Technology, Downstream
Catalent
Purification Development Scientist
AstraZeneca
Bioprocess Scientist (Downstream)
Global Channel Management
Senior Scientist mRNA
Lonza
Senior Scientist II, Early Pipeline Development
Novartis